CEO Richard Daly was paid $7,774,160 in fiscal year 2024, the 13th percentile of its disclosed peer group (SEC filing 0001193125-25-079097 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$7,774,160 Richard Daly total, FY2024 | 13th CEO pay percentile vs peers | 21:1 CEO-to-median pay ratio | 92.73% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Daly | $750,000 | $590,625 | $1,267,601 | $5,070,830 | $0 | $0 | $95,104 | $7,774,160 |
| President and CEO | ||||||||
| Michael Kalb | 525,000 | 350,625 | 1,036,803 | 4,147,345 | 0 | 0 | 121,163 | 6,180,936 |
| EVP and CFO | ||||||||
| Steven Miller | 560,000 | 352,800 | 523,797 | 2,095,377 | 0 | 0 | 13,800 | 3,545,774 |
| COO and CSO | ||||||||
| Jeffrey Del Carmen | 525,000 | 275,625 | 355,006 | 1,420,124 | 0 | 0 | 62,372 | 2,638,127 |
| CCO | ||||||||
| Preethi Sundaram | 485,000 | 254,625 | 355,006 | 1,420,124 | 0 | 0 | 13,800 | 2,528,555 |
| Chief Strategy Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Richard Daly | $7,774,160 | — | — | — |
| Michael Kalb | 6,180,936 | — | — | — |
| Steven Miller | 3,545,774 | 3,404,698 | 3,474,783 | ↑ +141,076 |
| Jeffrey Del Carmen | 2,638,127 | 2,506,066 | 2,386,432 | ↑ +132,061 |
| Preethi Sundaram | 2,528,555 | 2,145,798 | 2,138,461 | ↑ +382,757 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Catalyst Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CPRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CPRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CPRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Charles B. O'Keeffe | Director | $408,644 |
| David S. Tierney | Independent Director | $381,019 |
| Donald A. Denkhaus | Independent Director | $386,269 |
| Molly Harper | Independent Director | $439,144 |
| Patrick J. McEnany | Chair of the Board | $844,759 |
| Tamar Thompson | Independent Director | $381,019 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Patrick J. McEnany | Director | 2025-11-21 | A | 1,775 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | A | 6,894 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-11-21 | A | 5,603 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 5,161 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 2,030 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-11-21 | D | 7,872 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | D | 10,983 | 23 | 256,244 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 4 | 46,238 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 1,669 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | A | 6,855 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-08 | — | 5,652 | — | — | 4 insiders, 4 accrual rows | ||
| Molly Harper | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | A | 3,534 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 2,492 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | A | 8,039 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | A | 11,873 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | A | 7,067 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 2,780 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 6,746 | 23 | 155,563 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 15,527 | 23 | 360,195 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | A | 20,000 | 6 | 115,600 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 4,473 | 24 | 106,162 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-29 | — | 5,336 | — | — | 4 insiders, 4 accrual rows | ||
| Patrick J. McEnany | Director | 2025-12-29 | D | 26,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | D | 6,786 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | D | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | A | 14,000 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 2,623 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 8,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 3,839 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | D | 524 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | A | 26,334 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 2,369 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | A | 8,667 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 42,105 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | A | 7,139 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 10,577 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 7,139 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | A | 42,105 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 2,080 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-02-17 | — | 687 | — | — | 1 insider, 1 accrual row | ||
| Gregg Russo | Chief HR Officer | 2026-02-17 | D | 211 | — | — | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | A | 687 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | D | 743 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | A | 3,052 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-15 | — | 13,232 | — | — | 4 insiders, 8 accrual rows | ||
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,957 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 39,701 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 131,536 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,665 | 32 | 430,448 | Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 3,694 | 32 | 116,361 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 40,013 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 491,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 143,193 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 167,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 150,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 34,921 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 740,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 158,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 275,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 180,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 1,093,803 | 32 | 34,454,795 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 147,621 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 43,591 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 270,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 476 | 32 | 14,994 | Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 3,773 | 32 | 118,850 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 169,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 2,309 | 32 | 72,734 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 1,365,319 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 67,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 54,804 | 32 | 1,726,326 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 14,337 | 32 | 451,616 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 10,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 16,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 202,958 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 126,704 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 257,214 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,788 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 124,447 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 115,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 381,948 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 68,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 225,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 88,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 498,773 | 32 | 15,711,350 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 73,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 272,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 400,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 4,171,559 | 32 | 131,404,109 | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 2,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,349 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 146,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 185,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 383,314 | 32 | 12,074,391 | Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 69,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 132,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 242,501 | 32 | 7,638,782 | Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 21,416 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 271,266 | 32 | 8,544,879 | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,552 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 47,826 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 248,004 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 10,322 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 12,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 126,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Patrick J. McEnany | Director | 2025-11-21 | A | 1,775 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2025-11-21 | A | 6,894 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-11-21 | A | 5,603 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 5,161 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-11-21 | D | 2,030 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-11-21 | D | 7,872 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | D | 10,983 | 23 | 256,244 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-11-26 | A | 10,983 | 4 | 46,238 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-01 | D | 45,000 | 0 | 0 | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 1,669 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | A | 6,855 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | A | 3,534 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 2,492 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | A | 8,039 | — | — | Common | Form 4 ↗ |
| Tamar Thompson | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | A | 11,873 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-08 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-08 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | A | 7,067 | — | — | Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-08 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-08 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-08 | A | 1,413 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-08 | D | 1,413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-08 | D | 2,780 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 6,746 | 23 | 155,563 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 15,527 | 23 | 360,195 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | A | 20,000 | 6 | 115,600 | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-12 | D | 4,473 | 24 | 106,162 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | D | 26,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | D | 6,786 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | D | 14,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2025-12-29 | A | 14,000 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 2,623 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 6,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Compliance/Legal Officer | 2025-12-29 | A | 6,667 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 8,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | D | 3,839 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | D | 524 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2025-12-29 | A | 26,334 | — | — | Common | Form 4 ↗ |
| Molly Harper | Director | 2025-12-29 | A | 1,334 | — | — | Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2025-12-29 | D | 2,369 | — | — | Common | Form 4 ↗ |
| David S. Tierney | Director | 2025-12-29 | D | 1,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2025-12-29 | A | 8,667 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 42,105 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | A | 7,139 | — | — | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | D | 10,577 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 7,139 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-01-05 | A | 42,105 | — | — | Common | Form 4 ↗ |
| Michael Kalb | Executive Vice President & CFO | 2026-01-05 | D | 2,080 | — | — | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | D | 687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | D | 211 | — | — | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-02-17 | A | 687 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | D | 743 | — | — | Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-06-03 | A | 3,052 | — | — | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,957 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 39,701 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 131,536 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,665 | 32 | 430,448 | Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 3,694 | 32 | 116,361 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 40,013 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 491,160 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 143,193 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 11,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 8,039 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 167,918 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 150,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 34,921 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 740,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 6,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 11,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 158,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 275,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 180,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 1,093,803 | 32 | 34,454,795 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 7,067 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 147,621 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 6,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 43,591 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 270,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 476 | 32 | 14,994 | Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 3,773 | 32 | 118,850 | Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 169,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 2,309 | 32 | 72,734 | Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 1,365,319 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 106,873 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 67,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 54,804 | 32 | 1,726,326 | Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 135,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 14,337 | 32 | 451,616 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 10,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 16,534 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 202,958 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 126,704 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 257,214 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 13,788 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Molly Harper | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 98,652 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 124,447 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 115,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 381,948 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 33,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 68,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 225,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 32,257 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Del Carmen | Chief Commercial Officer | 2026-07-15 | D | 88,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 23,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 498,773 | 32 | 15,711,350 | Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 73,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 272,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 400,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 4,171,559 | 32 | 131,404,109 | Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 2,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 20,349 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Russo | Chief HR Officer | 2026-07-15 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 1,414 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamar Thompson | Director | 2026-07-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 146,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 185,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 29,524 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 383,314 | 32 | 12,074,391 | Common | Form 4 ↗ |
| Daniel J. Curran | Director | 2026-07-15 | D | 18,115 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 69,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 132,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 242,501 | 32 | 7,638,782 | Common | Form 4 ↗ |
| Michael Kalb | Chief Financial Officer | 2026-07-15 | D | 21,416 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 29,776 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 271,266 | 32 | 8,544,879 | Common | Form 4 ↗ |
| Donald A. Denkhaus | Director | 2026-07-15 | D | 5,468 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick J. McEnany | Director | 2026-07-15 | D | 3,552 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 47,826 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Miller | Chief Op. & Scientific Officer | 2026-07-15 | D | 248,004 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Tierney | Director | 2026-07-15 | D | 1,894 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Elsbernd | Chief Legal Officer | 2026-07-15 | D | 10,322 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William T. Andrews | Chief Medical Officer | 2026-07-15 | D | 12,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Daly | Director | 2026-07-15 | D | 126,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Preethi Sundaram | Chief Strategy Officer | 2026-07-15 | D | 137,553 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jeffrey Del Carmen | OPTION | 2024-11-21 | — | — | 137,553 | — | $1,420,124 |
| Preethi Sundaram | OPTION | 2024-11-21 | — | — | 137,553 | — | 1,420,124 |
| Richard Daly | OPTION | 2024-11-21 | — | — | 491,160 | — | 5,070,830 |
| Steven Miller | OPTION | 2024-11-21 | — | — | 202,958 | — | 2,095,377 |
| Michael Kalb | OPTION | 2024-01-01 | — | — | 257,214 | — | 2,399,996 |
| Michael Kalb | OPTION | 2024-11-21 | — | — | 169,248 | — | 1,747,349 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jeffrey Del Carmen | $0 | $0 | $1,420,124 | 0.0% |
| Preethi Sundaram | 0 | 0 | 1,420,124 | 0.0% |
| Richard Daly | 0 | 0 | 5,070,830 | 0.0% |
| Steven Miller | 0 | 0 | 2,095,377 | 0.0% |
| Michael Kalb | 0 | 0 | 4,147,345 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Kalb | Option | 169,248 | 21.12 | — |
| Michael Kalb | Option | 257,214 | 16.81 | — |
| Steven Miller | Option | 202,958 | 21.12 | — |
| Jeffrey Del Carmen | Option | 111,946 | 14.15 | — |
| Steven Miller | Option | 165,336 | 14.15 | — |
| Richard Daly | Option | 5,000 | 18.59 | — |
| Richard Daly | Option | 1,365,319 | 13.3 | — |
| Richard Daly | Option | 491,160 | 21.12 | — |
| Preethi Sundaram | Option | 75,000 | 5.49 | — |
| Steven Miller | Option | 48,667 | 18.59 | — |
| Jeffrey Del Carmen | Option | 30,000 | 4.7 | — |
| Jeffrey Del Carmen | Option | 29,334 | 18.59 | — |
| Jeffrey Del Carmen | Option | 137,553 | 21.12 | — |
| Preethi Sundaram | Option | 22,667 | 18.59 | — |
| Preethi Sundaram | Option | 95,462 | 14.15 | — |
| Preethi Sundaram | Option | 137,553 | 21.12 | — |
The compensation program is designed to provide a competitive level of base salary reflecting position responsibilities and strategic importance, a cash-based short-term incentive to recognize the achievement of annual goals, and long-term equity incentives to align management with long-term stockholder value creation and retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-20 | 82,734,939 | 6,484,020 | 203,472 | 92.73% | Passed |
| 2024 | 2024-05-21 | 84,194,484 | 5,468,681 | 181,674 | 93.9% | Passed |
| 2023 | 2023-08-22 | 72,610,991 | 2,909,780 | 437,050 | 96.15% | Passed |
| 2022 | 2022-09-19 | 66,515,582 | 2,124,782 | 111,352 | 96.9% | Passed |
| 2021 | 2021-12-03 | 59,092,977 | 3,432,904 | 246,626 | 94.51% | Passed |
| 2020 | 2020-08-20 | 56,150,772 | 1,880,451 | 412,646 | 96.08% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-05-20 | 92.73%a |
| 2024 | 2024-05-21 | 93.9%b |
| 2023 | 2023-08-22 | 96.15%c |
a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 21 : 1 |
|---|---|
| CEO total compensation | $7,774,160 |
| Median employee compensation | $370,800 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick J. McEnanyNot independent · Board Chair | $282,211 | $562,548 | — | — | — | $844,759 |
| Molly HarperIndependent · Lead Independent Director · Compensation · Corporate Governance · Nominating | 139,125 | 300,019 | — | — | — | 439,144 |
| Charles B. O'KeeffeNot standing for re-election | 108,625 | 300,019 | — | — | — | 408,644 |
| Donald A. DenkhausIndependent · Audit (Chair) · Corporate Governance · Nominating | 86,250 | 300,019 | — | — | — | 386,269 |
| Tamar ThompsonIndependent · Corporate Governance and Nominating (Chair) · Audit | 81,000 | 300,019 | — | — | — | 381,019 |
| David S. TierneyIndependent · Compensation (Chair) · Corporate Governance and Nominating | 81,000 | 300,019 | — | — | — | 381,019 |
| Richard J. DalyEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 21,000 / 15,750 / 10,500 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $778,211 |
| Equity awards (grant-date value) | $2,062,643 |
| All other compensation | $0 |
| Total cost of the board | $2,840,854 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Catalyst Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Catalyst Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 6 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 7 | Ultragenyx Pharmaceutical, Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 8 | Ani Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 9 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 10 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 11 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 12 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 13 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 14 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 15 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 16 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Catalyst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| Ani Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Ultragenyx Pharmaceutical, Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Richard Daly | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Executive Compensation”. As printed: 7,774,160. Filing ↗ |
| 2 | Section 01, Michael Kalb | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Executive Compensation”. As printed: 6,180,936. Filing ↗ |
| 3 | Section 01, Steven Miller | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Executive Compensation”. As printed: 3,545,774. Filing ↗ |
| 4 | Section 01, Jeffrey Del Carmen | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Executive Compensation”. As printed: 2,638,127. Filing ↗ |
| 5 | Section 01, Preethi Sundaram | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Executive Compensation”. As printed: 2,528,555. Filing ↗ |
| 6 | Section 03, Jeffrey Del Carmen OPTION | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r6 · c15 · span 337251–337260 |
| 7 | Section 03, Preethi Sundaram OPTION | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r7 · c15 · span 338583–338592 |
| 8 | Section 03, Richard Daly OPTION | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r2 · c15 · span 331869–331878 |
| 9 | Section 03, Steven Miller OPTION | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r5 · c15 · span 335892–335901 |
| 10 | Section 03, Michael Kalb OPTION | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t75 · r3 · c15 · span 333204–333213 |
| 11 | Section 03, Michael Kalb OPTION | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Grants of Plan-Based Awards for 2024” · grants of plan-based awards table. Filing ↗machine: t75 · r4 · c15 · span 334560–334569 |
| 12 | Section 07, pay ratio | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “CEO Pay Ratio”. As printed: 21 : 1. Filing ↗ |
| 13 | Section 08, Patrick J. McEnany | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 844,759. Filing ↗machine: span 167469–167476 |
| 14 | Section 08, Molly Harper | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 439,144. Filing ↗machine: span 169643–169650 |
| 15 | Section 08, Charles B. O'Keeffe | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 408,644. Filing ↗machine: span 170730–170737 |
| 16 | Section 08, Donald A. Denkhaus | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 386,269. Filing ↗machine: span 168544–168551 |
| 17 | Section 08, Tamar Thompson | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 381,019. Filing ↗machine: span 171826–171833 |
| 18 | Section 08, David S. Tierney | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 381,019. Filing ↗machine: span 172905–172912 |
| 19 | Section 08, Richard J. Daly | DEF 14A | 2025-04-11 | 0001193125-25-079097 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 20 | Section 02, Patrick J. McEnany 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000419 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Michael Kalb 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000418 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Michael Kalb 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000418 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Preethi Sundaram 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000422 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Brian Elsbernd 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000416 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Brian Elsbernd 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000416 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Richard J. Daly 2025-11-21 | Form 4 | 2025-11-24 | 0001161697-25-000413 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Jeffrey Del Carmen 2025-11-26 | Form 4 | 2025-11-28 | 0001161697-25-000430 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Jeffrey Del Carmen 2025-11-26 | Form 4 | 2025-11-28 | 0001161697-25-000430 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Jeffrey Del Carmen 2025-11-26 | Form 4 | 2025-11-28 | 0001161697-25-000430 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Patrick J. McEnany 2025-12-01 | Form 4 | 2025-12-03 | 0001161697-25-000432 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Patrick J. McEnany 2025-12-01 | Form 4 | 2025-12-03 | 0001161697-25-000432 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Patrick J. McEnany 2025-12-01 | Form 4 | 2025-12-03 | 0001161697-25-000432 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Preethi Sundaram 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000449 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Preethi Sundaram 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000449 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Molly Harper 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000446 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Molly Harper 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000446 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Patrick J. McEnany 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000447 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Jeffrey Del Carmen 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Jeffrey Del Carmen 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Tamar Thompson 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000450 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Steven Miller 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000448 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Brian Elsbernd 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000445 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Preethi Sundaram 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000449 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Jeffrey Del Carmen 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000443 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Brian Elsbernd 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000445 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Steven Miller 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000448 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Donald A. Denkhaus 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000444 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Patrick J. McEnany 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000447 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Tamar Thompson 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000450 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, David S. Tierney 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000451 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, David S. Tierney 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000451 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Donald A. Denkhaus 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000444 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Brian Elsbernd 2025-12-08 | Form 4 | 2025-12-10 | 0001161697-25-000445 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Molly Harper 2025-12-12 | Form 4 | 2025-12-16 | 0001161697-25-000462 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Molly Harper 2025-12-12 | Form 4 | 2025-12-16 | 0001161697-25-000462 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Molly Harper 2025-12-12 | Form 4 | 2025-12-16 | 0001161697-25-000462 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Molly Harper 2025-12-12 | Form 4 | 2025-12-16 | 0001161697-25-000462 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Molly Harper 2025-12-12 | Form 4 | 2025-12-16 | 0001161697-25-000462 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Richard J. Daly 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000488 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Patrick J. McEnany 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000493 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Patrick J. McEnany 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000493 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Molly Harper 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000492 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Steven Miller 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000494 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Steven Miller 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000494 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Preethi Sundaram 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000495 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, David S. Tierney 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000496 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Brian Elsbernd 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000491 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Donald A. Denkhaus 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000490 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Brian Elsbernd 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000491 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Preethi Sundaram 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000495 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Brian Elsbernd 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000491 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Donald A. Denkhaus 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000490 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Jeffrey Del Carmen 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000489 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Jeffrey Del Carmen 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000489 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Richard J. Daly 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000488 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Richard J. Daly 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000488 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Patrick J. McEnany 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000493 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Molly Harper 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000492 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Preethi Sundaram 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000495 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, David S. Tierney 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000496 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jeffrey Del Carmen 2025-12-29 | Form 4 | 2025-12-30 | 0001161697-25-000489 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Richard J. Daly 2026-01-05 | Form 4 | 2026-01-06 | 0001161697-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Michael Kalb 2026-01-05 | Form 4 | 2026-01-06 | 0001161697-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Richard J. Daly 2026-01-05 | Form 4 | 2026-01-06 | 0001161697-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Michael Kalb 2026-01-05 | Form 4 | 2026-01-06 | 0001161697-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Richard J. Daly 2026-01-05 | Form 4 | 2026-01-06 | 0001161697-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Michael Kalb 2026-01-05 | Form 4 | 2026-01-06 | 0001161697-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Gregg Russo 2026-02-17 | Form 4 | 2026-02-19 | 0001161697-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Gregg Russo 2026-02-17 | Form 4 | 2026-02-19 | 0001161697-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Gregg Russo 2026-02-17 | Form 4 | 2026-02-19 | 0001161697-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, William T. Andrews 2026-06-03 | Form 4 | 2026-06-05 | 0001161697-26-000132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, William T. Andrews 2026-06-03 | Form 4 | 2026-06-05 | 0001161697-26-000132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Daniel J. Curran 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Daniel J. Curran 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, William T. Andrews 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Molly Harper 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, William T. Andrews 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, William T. Andrews 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Jeffrey Del Carmen 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000174 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Gregg Russo 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000181 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Tamar Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000183 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Daniel J. Curran 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Michael Kalb 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000178 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, William T. Andrews 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Donald A. Denkhaus 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000175 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Patrick J. McEnany 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000179 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Steven Miller 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000180 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, David S. Tierney 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000184 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Brian Elsbernd 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, William T. Andrews 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Richard J. Daly 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000173 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Preethi Sundaram 2026-07-15 | Form 4 | 2026-07-17 | 0001161697-26-000182 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 06, 2025 vote | Form 8-K | 2025-05-23 | 0001193125-25-125872 | Item 5.07 · say-on-pay result. As reported: 92.73% (votes for as printed: 82,734,939). Filing ↗ |
| 221 | Section 06, 2024 vote | Form 8-K | 2024-05-21 | 0001193125-24-144049 | Item 5.07 · say-on-pay result. As reported: 93.9% (votes for as printed: 84,194,484). Filing ↗ |
| 222 | Section 06, 2023 vote | Form 8-K | 2023-08-25 | 0001193125-23-221544 | Item 5.07 · say-on-pay result. As reported: 96.15% (votes for as printed: 72,610,991). Filing ↗ |
| 223 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 224 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 225 | Section 09b board cost (computed) | Computed | — | — | Cash 778,211 + equity 2,062,643 + all other 0 = 2,840,854, summed across the director compensation table rows.machine: formula: Σ = 2,840,854 |
| 226 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗ |
| 227 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 228 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 229 | Insmed Incorporated, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 230 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 231 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 232 | Ultragenyx Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical, Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 233 | Ani Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in Ani Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 234 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 235 | Amphastar Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 236 | Acadia Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 237 | Dynavax Technologies Corporation, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. Filing ↗ |
| 238 | Harmony Biosciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 239 | Catalyst Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. Filing ↗ |
| 240 | Ironwood Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191 |
| 241 | Collegium Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 242 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 243 | Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 244 | Section 10a, Dynavax Technologies Corporation reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies Corporation's most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 245 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 246 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 247 | Section 10a, Ironwood Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-050325 | Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 248 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 249 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 250 | Section 10a, Insmed Incorporated reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 251 | Section 10a, Collegium Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 252 | Section 10a, Ultragenyx Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
| 253 | Section 10a, Ani Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001023024-26-000039 | Ani Pharmaceuticals, Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 254 | Section 10a, Acadia Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | Acadia Pharmaceuticals Inc. names Catalyst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 255 | Section 10a, Harmony Biosciences Holdings, Inc. reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalyst Pharmaceuticals. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.